Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.
Christopher K RaynerKaren Louise JonesChristopher K RaynerChinmay S MaratheMichael HorowitzPublished in: Diabetes care (2022)